You are here

Drug Use Investigation Of Gabapentin

Last updated on October 11, 2019

Study Location
Eligibility criteria
The disease, disorder, syndrome, illness, or injury that is being studied.
Partial Epilepsies
Females and Males
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Patients need to be taking Gabapentin in order to be enrolled in the surveillance

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

Patients not taking Gabapentin

Drug Use Investigation Of Gabapentin


Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center


[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Partial Epilepsies
All Genders
Multiple Sites
Descriptive Information
Brief TitleDrug Use Investigation Of Gabapentin
Official TitleDrug Use Investigation Of Gabapen
Brief SummaryThe objective of the this surveillance is to collect information about 1)adverse drug reactions not expected from the LPD (unknown adverse drug reactions), 2) the incidence of adverse drug reactions in this surveillance, and 3) factors considered to affect the safety and/or efficacy of this drug.
Detailed DescriptionAll the patients whom an investigator prescribes the first Gabapentin should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.
Study TypeObservational
Study DesignObservational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up DurationNot Provided
BiospecimenNot Provided
Sampling MethodProbability Sample
Study PopulationThe patients whom an investigator involving A9451163 prescribes the Gabapentin
ConditionEpilepsies, Partial
InterventionDrug: Gabapentin

GABAPEN Tablets 200mg, GABAPEN Tablets 300mg, GABAPEN Tablets 400mg. GABAPEN is Brand name in Japan.

Dosage, frequency: According to Japanese LPD, "Normally, oral gabapentin 600 mg, 3 div., should be given on the first day of administration and an effective dose of 1200mg, 3 div, should be given on day 2. From day 3 on, adults should be maintained on oral gabapentin 1200 mg to 1800 mg, 3 div. Subsequently, the maintenance dose should be suitably adjusted depending on the symptoms (up to a maximum daily dose of 2400 mg)".

Duration: According to the protocol of A9451163, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 12 weeks after the first administration.

Study Groups/CohortsGabapentin
Patients taking Gabapentin
Intervention: Drug: Gabapentin
Publications *Not Provided

*   Includes publications given by the data provider as well as publications
identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment StatusCompleted
Actual Enrollment
 (submitted: June 10, 2014)
Original Estimated Enrollment
 (submitted: December 3, 2007)
Actual Study Completion DateMay 2014
Actual Primary Completion DateMay 2014   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

Patients need to be taking Gabapentin in order to be enrolled in the surveillance

Exclusion Criteria:

Patients not taking Gabapentin

Sexes Eligible for Study:All
AgesChild, Adult, Older Adult
Accepts Healthy VolunteersNo
ContactsContact information is only displayed when the study is recruiting subjects
Listed Location CountriesNot Provided
Removed Location Countries  
Administrative Information
NCT NumberNCT00567268
Other Study ID NumbersA9451163
Has Data Monitoring CommitteeNo
U.S. FDA-regulated ProductNot Provided
IPD Sharing StatementNot Provided
Responsible PartyPfizer
Study SponsorPfizer
CollaboratorsNot Provided
Study Director:Pfizer Call CenterPfizer
PRS AccountPfizer
Verification DateSeptember 2015


Contact a representative by phone, email, or visiting the study website. Please see the references below:


Pfizer Clinical Trials Contact Center




[email protected]

Call Now